赵晓燕, 赵连友, 郑强荪, 张兴凯. 过氧化物酶增殖物激活受体α激动剂对心脏成纤维细胞增殖的抑制作用[J]. 心脏杂志, 2011, 23(1): 11-15.
    引用本文: 赵晓燕, 赵连友, 郑强荪, 张兴凯. 过氧化物酶增殖物激活受体α激动剂对心脏成纤维细胞增殖的抑制作用[J]. 心脏杂志, 2011, 23(1): 11-15.
    Inhibitory effect of peroxisome proliferator-activated receptor-α agonist on proliferation of cardiac fibroblasts[J]. Chinese Heart Journal, 2011, 23(1): 11-15.
    Citation: Inhibitory effect of peroxisome proliferator-activated receptor-α agonist on proliferation of cardiac fibroblasts[J]. Chinese Heart Journal, 2011, 23(1): 11-15.

    过氧化物酶增殖物激活受体α激动剂对心脏成纤维细胞增殖的抑制作用

    Inhibitory effect of peroxisome proliferator-activated receptor-α agonist on proliferation of cardiac fibroblasts

    • 摘要: 目的: 探讨过氧化物酶增殖物激活受体α(PPARα)激动剂非诺贝特(fenofibrate)对糜酶介导的大鼠心脏成纤维细胞(CFs)增殖的影响及作用机制。方法: 用胰酶消化法分离、培养新生SD大鼠的CFs。采用3H-脱氧胸腺嘧啶核苷(3H-TdR)掺入法测定CFs的DNA合成,用流式细胞术分析细胞周期,用RT-PCR检测PPARα 及转化生长因子β1(TGF-β1)mRNA的表达。结果: ①以不同浓度的非诺贝特预处理后,CFs的3H-TdR掺入量呈浓度依赖性减少,其中50和100 μmol/L组均较糜酶组明显减少(分别为P<0.05和P<0.01)。②随着非诺贝特浓度的增加,CFs在G0/G1期的百分率逐渐增加,S期的百分率和增殖指数逐渐减少,其中50和100 μmol/L组与糜酶组比较,上述各项指标均有显著性差异(分别为P<0.05和P<0.01)。③以25、50和100 μmol/L非诺贝特预处理后,PPARα mRNA表达的水平呈浓度依赖性增加,其中50和100 μmol/L组均较糜酶组显著增加(分别为P<0.05和P<0.01)。④随着非诺贝特浓度的增加,TGF-β1 mRNA表达水平呈递减趋势,其中50和100 μmol/L组均较糜酶组明显减少(P<0.01)。结论: PPARα 激动剂非诺贝特以浓度依赖的方式抑制糜酶诱导的大鼠CFs增殖的作用,其机制与PPARα基因表达的上调和TGF-β1基因表达的下调有关,提示PPARα 和TGF-β1这两条信号通路可能存在信息交流。

       

      Abstract: AIM: To investigate the effect of peroxisome proliferator-activated receptor-α (PPARα) agonist fenofibrate on the proliferation of rat cardiac fibroblasts (CFs) induced by chymase and its mechanism of action. METHODS: Cultured CFs from neonatal SD rats were isolated by trypsinization and the DNA synthesis and cellular cycle of the CFs were evaluated, respectively, by 3H-TdR incorporation and flow cytometry. mRNA expressions of PPARα and TGF-β1 in the CFs were determined by RT-PCR. RESULTS: Pretreatment with fenofibrate decreased the 3H-TdR incorporation of the CFs in a concentration-dependent manner. The 3H-TdR incorporations pretreated with 50 and 100 μmol/L fenofibrate were significantly lower than those in the chymase group (P<0.05, P<0.01). Cellular cycle analysis showed that pretreatment with 50 and 100 μmol/L fenofibrate markedly increased the cellular percentage in G0/G1 stage and decreased the cellular percentage in S stage and proliferation index compared with those in the chymase group (P<0.05, P<0.01). Pretreatment with fenofibrate increased the PPARα mRNA and decreased the TGF-β1 mRNA in a dose-dependent manner. PPARα mRNA pretreated with 50 and 100 μmol/L fenofibrate was higher than in the chymase group (P<0.05, P<0.01) and the TGF-β1 mRNA was lower than in the chymase group (P<0.01). CONCLUSION: PPARα agonist fenofibrate inhibits the proliferation of rat CFs induced by chymase possibly through the upregulation of PPARα mRNA and the downregulation of TGF-β1 mRNA, suggesting that there may be cross-talk between the PPARα and TGF-β1 signal pathways.

       

    /

    返回文章
    返回